Compare DexCom, Inc. (DXCM) vs Toronto-Dominion Bank (TD) Price & Performance

DXCM trades at $77.31, up 4.3% on the day, with a bullish technical outlook as it approaches resistance near $78. The company reported strong earnings beats in recent quarters, with Q1 2026 EPS of $0.56 surpassing expectations of $0.47. Revenue growth accelerated to $4.66 billion in 2025, while net income margin expanded to 17.93%. Recent regulatory approvals, including Health Canada authorization for the G7 15-day CGM, support continued international expansion.

The stock offers growth potential with analyst consensus price target of $84.33, though high valuation multiples (P/E 31.21) and competition in the CGM market present risks. Expansion into non-insulin Type 2 diabetes and pediatric markets could drive future revenue, but commercial uptake remains unproven. Institutional sentiment remains strongly bullish with 80% buy ratings.

TD trades at $123.51, up 0.51% today, with a bullish technical signal from moving averages and a consensus analyst price target of $153.00. Recent quarterly earnings have consistently beaten expectations, with Q1 2026 EPS of $1.74 surpassing the $1.63 estimate. Revenue grew to $61.28 billion in 2025, and the company maintains a strong net income margin of 23.38%. A dividend of $1.12 per share is scheduled for payment on July 31, 2026.

The outlook for TD is positive, supported by earnings momentum and analyst confidence, though risks include volatile cash flows from operations and rising debt levels. The stock's current valuation at a P/E of 20.8 appears reasonable relative to growth, positioning it as a candidate for long-term dividend growth despite near-term overbought technical conditions.